by Dr. Renée Deehan Kenney, Senior Vice President of Research & Development at Selventa
March 11, 2015 at 12pm ET
RA patients are faced with a myriad of therapeutic choices after failure to respond to first line therapies. While this is encouraging, RA is a progressive disease and time spent on the wrong therapy results in irrevocable disease progression. ClarifyRA is an attempt towards providing a holistic diagnostic that not only provides a molecular measure of patient’s disease activity but also information about the likelihood of response to treatment.
About Dr. Renée Deehan Kenney
Dr. Renée Deehan Kenney joined Selventa, a personalized medicine company that specializes in working with large-scale molecular and clinical data in 2006. As Head of Research, she develops and executes the scientific strategy for Selventa’s internal discovery programs as well as consulting services. She leverages her understanding of both the industry and client needs to develop custom strategies that translate scientific challenges into navigable solutions that are predicated on her fundamental belief that a comprehensive understanding of the molecular basis of an individual patient’s disease is required for successful target discovery and biomarker development and ultimately for personalized medicine in the clinic. Dr. Deehan Kenney has led over 50 collaborations with pharmaceutical, consumer product, and academic partners. Before Selventa, she was earning her Ph.D in molecular and cell biology at the University of California, Berkeley and holds a BSE in engineering from the University of Pennsylvania.
Orion Bionetworks is a Cambridge, MA, non-profit 501(c)(3) research organization that builds Bionetwork Alliance communities to assemble and integrate high-dimensional biomarker, biosensor, and phenotypic data and advance knowledge discovery through the power of predictive analytics and computer modeling to accelerate the development of new diagnostics, treatments, and cures for brain disorders.
Orion’s webinar series fosters an exchange of knowledge on the latest breakthroughs in a variety of technical fields including bioinformatics, computational modeling, biomarker research, and nanotechnologies, and discusses how these can be utilized to accelerate time to cure for brain disease. We are inviting expert speakers to submit proposals for future webinars on the above topics. Each webinar is 50 minutes in length, followed by a 10-minute Q&A with questions submitted virtually by the participants. All webinars are free and open to the public.